AstraZeneca, ai
AstraZeneca is extending its work with Immunai through a multiyear collaboration that aims to implement its ...
Immunai already has strategic agreements with 30 pharmaceuticals companies, most of them involving much smaller financial ...
Monday, AstraZeneca Plc AZN released high-level results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) compared to the investigator’s choice of chemotherapy.
The newly launched “What Science Can Do” campaign, a longstanding tagline for AstraZeneca, centers around the stories of two patients who have benefitted from the company’s therapeutics.
AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer in a late ...
(RTTNews) - AstraZeneca plc (AZN, AZN.L) announced on Monday that the high-level results from the TROPION-Breast01 Phase III trial of datopotamab deruxtecan or Dato-DXd compared to the ...
AstraZeneca revealed its experimental breast cancer drug did not succeed in prolonging the survival of patients with the disease. Britain's largest pharmaceutical business said the trial focused ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Vandana Singh AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback